• 1
    Maroko PR, Kjekshus JK, Sobel BE, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971; 43:6782.
  • 2
    Reimer KA, Rasmussen MM, Jennings RB. Reduction by propranolol of myocardial necrosis following temporary coronary artery occlusion in dogs. Circ Res. 1973; 33:35363.
  • 3
    Wilhelmsson C, Vedin JA, Wilhelmsen L, Tibblin G, Werko L. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet. 1974; 2:115760.
  • 4
    Snow PJ. Effect of propranolol in myocardial infarction. Lancet. 1965; 2:5513.
  • 5
    Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008; 117:296329.
  • 6
    Center for Medicare & Medicaid Services. G-Code Specifications and Instruction for Clinical Measures: Physician Voluntary Reporting Program (PVRP). CMS, US Dept of Health & Human Services, 23 December 2005. Available at: Accessed October 14, 2009.
  • 7
    Balcon R, Jewitt DE, Davies JP, et al. A controlled trial of propranolol in acute myocardial infarction. Lancet. 1966; 2:91820.
  • 8
    Clausen J, Felsby M, Jorgensen FS, et al. Absence of prophylactic effect of propranolol in myocardial infarction. Lancet. 1966; 2:9204.
  • 9
    Evemy KL, Pentecost BL. Intravenous and oral practolol in the acute stages of myocardial infarction. Eur J Cardiol. 1978; 7:3918.
  • 10
    Peter T, Norris RM, Clarke ED, et al. Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation. 1978; 57:10915.
  • 11
    Norris RM, Clarke ED, Sammel NL, et al. Protective effect of propranolol in threatened myocardial infarction. Lancet. 1978; 2:9079.
  • 12
    Norris RM, Sammel NL, Clarke ED, et al. Treatment of acute myocardial infarction with propranolol. Further studies on enzyme appearance and subsequent left ventricular function in treated and control patients with developing infarcts. Br Heart J. 1980; 43:61722.
  • 13
    Yusuf S, Sleight P, Rossi P, et al. Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation. 1983; 67(6 Pt 2):I3241.
  • 14
    Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med. 1984; 310:915.
  • 15
    Norris RM, Barnaby PF, Brown MA, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet. 1984; 2:8836.
  • 16
    Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J. 1985; 6:199226.
  • 17
    Owensby DA, O’Rourke MF. Failure of intravenous pindolol to reduce the hemodynamic determinants of myocardial oxygen demand or enzymatically determined infarct size in acute myocardial infarction. Aust N Z J Med. 1985; 15:70411.
  • 18
    Salathia KS, Barber JM, McIlmoyle EL, et al. Very early intervention with metoprolol in suspected acute myocardial infarction. Eur Heart J. 1985; 6:1908.
  • 19
    Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986; 2:5766.
  • 20
    Heber ME, Rosenthal E, Thomas N, et al. Effect of labetalol on indices of myocardial necrosis in patients with suspected acute infarction. Eur Heart J. 1987; 8:1118.
  • 21
    Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991; 83:42237.
  • 22
    Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 1993; 22:40716.
  • 23
    Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366:162232.
  • 24
    β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982; 247:170714.
  • 25
    Pedersen TR. The Norwegian multicenter study of Timolol after myocardial infarction. Circulation. 1983; 67(6 Pt 2):I4953.
  • 26
    Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 1983; 67(6 Pt 2):I2632.
  • 27
    Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001; 134:66394.
  • 28
    Al-Reesi A, Al-Zadjali N, Perry J, et al. Do beta-blockers reduce short-term mortality following acute myocardial infarction? A systematic review and meta-analysis. Can J Emerg Med. 2008; 10:21523.